Methods for treating idiopathic pulmonary fibrosis
The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IFF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.
1. A method for treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, the method comprising:
(a) taking a baseline measurement of a pulmonary radiographic parameter, wherein the pulmonary radiographic parameter is ground glass opacity;
(b) administering at least 15 mg/kg of an anti-CTGF antibody every three weeks, thereby stabilizing or producing at least a 2% reduction in ground glass opacity compared to the baseline measurement, wherein the anti-CTGF antibody is identical to the antibody produced by the cell line identified by ATCC Accession No. PTA-6006.
2. The method of claim 1 wherein administration of the anti-CTGF antibody also stabilizes or produces at least a 2% reduction, compared to a baseline measurement, in the pulmonary radiographic parameter selected from the group consisting of fibrosis and honeycomb formation.
3. The method of claim 1 , wherein the subject has a forced vital capacity percent (FVC %) predicted of greater than about 55% prior to treatment with the anti-CTGF antibody.
4. The method of claim 1 wherein the subject has less than 50% parenchymal fibrosis prior to treatment with the anti-CTGF antibody.
5. The method of claim 1 , wherein the subject has less than 25% honeycombing within the whole lung prior to treatment with the anti-CTGF antibody.